Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer

Oncology

Volumn 63, Issue 1, 2002, Pages 16-22

  Sugiyama, Toru ^a,n   Yakushiji, Michiaki ^a   Kamura, Toshiharu ^a   Ikeda, Masanori ^b   Umesaki, Naohiko ^c   Hasegawa, Kazuo ^d   Ishikawa, Mutsuo ^e   Saji, Fumitaka ^f   Hiura, Masamichi ^g   Takahashi, Takeshi ^h   Sato, Shinji ⁱ   Ochiai, Kazunori ^j   Kikkawa, Fumitaka ^k   Takeuchi, Shoshichi ^l   Ohashi, Yasuo ^m   Noda, Kiichiro ^b  

^a KURUME UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^e ASAHIKAWA MEDICAL COLLEGE   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h Niigata Prefectural Cancer Center   (Japan)

ⁱ TOHOKU UNIVERSITY   (Japan)

^j JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NAGOYA UNIVERSITY   (Japan)

^l Kitatama Hospital   (Japan)

^m UNIVERSITY OF TOKYO   (Japan)

ⁿ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chemotherapy naive patients; Cisplatin; Irinotecan; Ovarian cancer

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGE; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG TOXICITY; NAUSEA; NEUTROPENIA; OVARY CANCER; PERFORMANCE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 18544379328     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065715     Document Type: Article

References (34)

1. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103
2. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy. A Gynecologic Oncology Group Study
3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
4. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer: Three year results
5. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group Trial (GOG 158)
6. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial
7. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin
8. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
9. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trial Group Study
10. Topotecan in platinum- and paclitaxel-resistant ovarian cancer
11. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
12. Phase II study of gemcitabine (2′, 2″-difluorodeoxycytidine) in previously treated ovarian cancer patients
13. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease
14. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
15. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice
16. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
17. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
18. CPT-11: A new derivative of camptothecin, for the treatment of refractory or relapsed small-cell lung cancer
19. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer
20. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gynecologic cancers
21. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against lung tumor xenografts
22. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
23. Phase I study of irinotecan (CPT-11) in combination with cisplatin in cervical and ovarian carcinoma
24. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer
25. Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer
26. Toxicity and response criteria of the Eastern Cooperative Oncology Group
27. Non parametric estimation from incomplete observations
28. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study
29. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer
30. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study
31. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhoea
32. Phase II study of irinotecan combined with cisplatin in patients with untreated small-cell lung cancer
33. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer